Stockholm, Sweden – There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia, according to a study led by researchers at Karolinska Institutet. Both forms of treatment produced a significant reduction in symptoms in people affected by the disease....
Latest News
Recall the saying “there are a thousand ways to skin a cat”? Researchers are rephrasing it in regard to the mosquito. Fifty years ago, we thought that the war against malaria was pretty much won. We had quinine and chloroquine, which were effective against the parasite that causes the disease....
ORLANDO — Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are...
EL PASO — Two-year-old Emmanuel Gonzalez felt the sun on his face for the first time in weeks Sunday. He has a rare immune system disorder and had to stay in his room at Providence Memorial Hospital while he got well enough to make his first trip down to the...
BIRMINGHAM, Ala. – Researchers have discovered the novel mechanism that underlies a previously reported observation that infection by group A Streptococcus bacteria reduces the risk of later developing Type 1 diabetes. The Journal of Immunology reports that vaccination of neonatal mice with group A Streptococcus promoted a clonal expansion of...
CARLSBAD, Calif. — Tyra Biosciences, Inc. a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it has initiated the SURF201 Phase 1 study of TYRA-200 and provided positive updates on its oral FGFR3-selective inhibitor, TYRA-300....
CARLSBAD, Calif. — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral...
MINNEAPOLIS/ST. PAUL — Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder that affects children and adults, and can lead to kidney failure. New findings from a team led by the University of Minnesota Medical School show patients with FSGS who were treated with the medication sparsentan experienced improved kidney function—making...
Fayetteville, Arkansas – The U.S. Department of Defense awarded just under $514,000 to an interdisciplinary team of researchers at the University of Arkansas to study the efficacy of “self-delivering” gene editors in the treatment of Duchenne Muscular Dystrophy, or DMD. DMD results from a mutation in the dystrophin gene and...
PHILADELPHIA – Amicus Therapeutics (Nasdaq: FOLD) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat for AT-GAA, the Company’s investigational two-component therapy for the treatment of Pompe disease. Pompe disease...